Soligenix, Inc. Common Stock (SNGX) is a publicly traded Healthcare sector company. As of May 21, 2026, SNGX trades at $0.39 with a market cap of $6.06M and a P/E ratio of -0.17. SNGX moved +3.22% today. Year to date, SNGX is -72.88%; over the trailing twelve months it is -80.31%. Its 52-week range spans $0.28 to $6.23. Analyst consensus is buy with an average price target of $1.50. Rallies surfaces SNGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Soligenix Halts Phase 3 HyBryte Trial for Futility, Holds $6M Cash Runway: Soligenix halted its pivotal Phase 3 FLASH2 trial of HyBryte after an interim analysis found no efficacy signal at 18 weeks, despite previous positive results at six weeks. The company reported a $2.8M net loss for Q1 2026 and holds $6.0M cash, providing runway into Q2 2027.
| Metric | Value |
|---|---|
| Price | $0.39 |
| Market Cap | $6.06M |
| P/E Ratio | -0.17 |
| EPS | $-2.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.23 |
| 52-Week Low | $0.28 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-11.08M |
| Gross Margin | 0.00% |
1 analysts cover SNGX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $1.50.